Association of HLA ‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients
HLA · 2026-11 · 108 (5)
DOI: 10.1111/tan.71082 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, online erschienen am 06.11.2026. Verfasst von Leonie Ballmer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, BK Virus, HLA-B Antigens. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Natural killer (NK) cell education and function depend on HLA‐E expression, influenced by the dimorphic HLA‐B leader peptide (−21M vs. −21T). NK cells help control BK polyomavirus (BKPyV) and cytomegalovirus (CMV) after kidney transplantation, but the HLA‐B leader's role is unclear. We retrospectively studied 700 kidney transplants with high‐resolution recipient/donor HLA typing, determining the recipient's HLA‐B leader genotype (MM 6%, MT 39%, TT 55%) and recipient/donor constellation (345/700 [49%] matched, 355/700 [51%] mismatched). Associations with 1‐year occurrence and severity of BKPyV (decoy cell shedding, BKPyV‐DNAemia, presumptive BKPyV‐associated nephropathy [BKPyVAN]) and CMV (DNAemia, disease) were assessed with univariate analyses and multivariable Cox and logistic regression. One‐year incidence of decoy cell shedding was similar across genotypes (MM 28.3%, MT 29.0%, TT 33.5%; p = 0.37) and between matched and mismatched recipients (31.0% vs. 31.8%; p = 0.79); BKPyV‐DNAemia incidence likewise did not differ by genotype (MM 19.6%, MT 16.5%, TT 18.9%; p = 0.73) or constellation (15.9% vs. 20.0%; p = 0.16). In multivariable models, neither genotype nor constellation was associated with decoy cell shedding, BKPyV‐DNAemia, or development of presumptive BKPyVAN. CMV‐DNAemia incidence also did not differ by genotype (MM 19.6%, MT 30.9%, TT 28.8%; p = 0.35) or constellation (27.0% vs. 31.0%; p = 0.25). In multivariable models, neither genotype nor constellation was associated with CMV‐DNAemia or development of CMV disease. In conclusion, the HLA‐B leader is neither associated with the occurrence nor the severity of BKPyV and CMV infections within the first year posttransplant in kidney allograft recipients. This argues against using HLA‐B leader information to guide BKPyV or CMV screening strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
- Translational Virus Immunity Pathology, Immunology Research, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
- Translational Virus Immunity Pathology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
- HLA-Diagnostics and Immunogenetics, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Leonie Ballmer, Matthias Diebold, Hans H Hirsch, Gideon Hönger, Caroline Wehmeier, Stefan Schaub
Zitieren
APA
Ballmer, L., Diebold, M., Hirsch, H. H., Hönger, G., Wehmeier, C., & Schaub, S. (2026). Association of HLA ‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients. HLA, 108(5). https://doi.org/10.1111/tan.71082
Vancouver
Ballmer L, Diebold M, Hirsch HH, Hönger G, Wehmeier C, Schaub S. Association of HLA ‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients. HLA. 2026;108(5). doi:10.1111/tan.71082
BibTeX
@article{Ballmer2026,
author = {Ballmer, Leonie and Diebold, Matthias and Hirsch, Hans H and Hönger, Gideon and Wehmeier, Caroline and Schaub, Stefan},
title = {Association of HLA ‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients},
journal = {HLA},
year = {2026},
volume = {108},
number = {5},
doi = {10.1111/tan.71082}
}
EUVIMED